catalym
Posted by catalym
September 26, 2022
September 26, 2022

CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the US

CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced...

Read More
catalym
Posted by catalym
September 10, 2022
September 10, 2022

CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination

CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for...

Read More
catalym
Posted by catalym
September 5, 2022
catalym
Posted by catalym
March 1, 2022
March 1, 2022

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase...

Read More
catalym
Posted by catalym
November 12, 2021
November 12, 2021

CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference

CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002...

Read More
trophic
Posted by trophic
October 11, 2021
October 11, 2021

CatalYm Presents Updated Tolerability & Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human Clinical Trial...

CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human...

Read More
trophic
Posted by trophic
September 30, 2021
September 30, 2021

CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference...

CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in...

Read More
piomat
Posted by piomat
May 20, 2021
May 20, 2021

CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting

CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody...

Read More
piomat
Posted by piomat
May 19, 2021
May 19, 2021

CatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation

CatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation CatalYm-Bioequity-Corp-presentation-May-2021...

Read More
piomat
Posted by piomat
May 4, 2021
May 4, 2021

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer Munich,...

Read More